Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

CBD-Microglia PET Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04398719
Recruitment Status : Recruiting
First Posted : May 21, 2020
Last Update Posted : April 20, 2021
Sponsor:
Collaborator:
National Center for Complementary and Integrative Health (NCCIH)
Information provided by (Responsible Party):
Rajiv Radhakrishnan, Yale University

Brief Summary:
This study aims to examine the effect of cannabidiol (CBD) pre-treatment on brain microglial activation in healthy human subjects. Secondarily, this study aims to examine the effect of cannabidiol (CBD) pre-treatment on central pain-sensitization in healthy human subjects.

Condition or disease Intervention/treatment Phase
CBD Healthy Radiation: [11C]PBR28 Drug: Low-dose lipopolysaccharide Drug: Intradermal Capsaicin Early Phase 1

Detailed Description:
This study aims to examine the effect of cannabidiol (CBD), pre-treatment, as Epidiolex, on brain microglial activation in healthy human subjects using [11C]PBR28 PET imaging. Secondarily, this study aims to examine the effect of cannabidiol (CBD) pre-treatment on central pain-sensitization in healthy human subjects. Lastly, this research study will also examine the relationship between brain microglial activation and central pain sensitization with CBD pre-treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Other
Official Title: Effect of Cannabidiol on Microglial Activation and Central Pain-Sensitization
Estimated Study Start Date : May 4, 2021
Estimated Primary Completion Date : August 31, 2022
Estimated Study Completion Date : March 1, 2023

Resource links provided by the National Library of Medicine

Drug Information available for: Capsaicin

Arm Intervention/treatment
Active Comparator: CBD Radiation: [11C]PBR28
The radiotracer, [11C]PBR28, will be administered at the beginning of each PET scan
Other Name: PET scan

Drug: Low-dose lipopolysaccharide
Subjects will receive intravenous lipopolysaccharide.
Other Name: LPS

Drug: Intradermal Capsaicin
A small dose of capsaicin will be administered by intradermal injection.

Placebo Comparator: Placebo Radiation: [11C]PBR28
The radiotracer, [11C]PBR28, will be administered at the beginning of each PET scan
Other Name: PET scan

Drug: Low-dose lipopolysaccharide
Subjects will receive intravenous lipopolysaccharide.
Other Name: LPS

Drug: Intradermal Capsaicin
A small dose of capsaicin will be administered by intradermal injection.




Primary Outcome Measures :
  1. Microglial activation using [11C]PBR28 PET imaging [ Time Frame: 10 Days ]
    Difference in microglial activation ([11C]PBR28 VT levels) between the 2 groups (e.g., CBD vs. placebo)


Secondary Outcome Measures :
  1. Capsaicin-induced hyperalgesia [ Time Frame: 10 Days ]
    Difference in capsaicin-induced hyperalgesia between the 2 groups (e.g., CBD vs. placebo)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Men and women aged 18- 55 years
  2. No significant medical or neurological illness
  3. No implanted metal devices that may pose a risk during MRI scanning
  4. Within the annual permissible radiation exposure
  5. Able to provide written informed consent.

Exclusion Criteria:

  1. Current use of any medications
  2. Presence of metal in the body
  3. Pregnancy or lactation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04398719


Contacts
Layout table for location contacts
Contact: Rajiv Radhakrishnan, MD 203-974-7489 rajiv.radhakrishnan@yale.edu
Contact: Mohini Ranganathan, MD (203)932-5711 ext 2546 mohini.ranganathan@yale.edu

Locations
Layout table for location information
United States, Connecticut
Connecticut Mental Health Center Recruiting
New Haven, Connecticut, United States, 06519
Contact    203-974-7775      
Principal Investigator: Rajiv Radhakrishnan, MD         
Principal Investigator: Mohini Ranganathan, MD         
Sponsors and Collaborators
Yale University
National Center for Complementary and Integrative Health (NCCIH)
Investigators
Layout table for investigator information
Principal Investigator: Rajiv Radhakrishnan, MD Yale University
Layout table for additonal information
Responsible Party: Rajiv Radhakrishnan, Assistant Professor of Psychiatry, Yale University
ClinicalTrials.gov Identifier: NCT04398719    
Other Study ID Numbers: 2000026320
First Posted: May 21, 2020    Key Record Dates
Last Update Posted: April 20, 2021
Last Verified: April 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Rajiv Radhakrishnan, Yale University:
Control
PET Scan
MRI Scan
Central Pain-Sensitization
Additional relevant MeSH terms:
Layout table for MeSH terms
Capsaicin
Antipruritics
Dermatologic Agents
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs